All per share figures in this news release reflect the 2-for-1 common stock split that Henry Schein completed during the third quarter of 2017.
Adjusts 2017 full year diluted EPS guidance range, introduces 2018 diluted EPS guidance
MELVILLE, N.Y., Nov. 6, 2017 /PRNewswire/ -- Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care products and services to office-based dental, animal health, and medical practitioners, today reported record third quarter financial results. All per share figures in this news release reflect the 2-for-1 common stock split that Henry Schein completed during the third quarter of 2017.
Net sales for the quarter ended September 30, 2017 were $3.2 billion, an increase of 10.3% compared with the third quarter of 2016. This consisted of 8.8% growth in local currencies and a 1.5% increase related to foreign currency exchange. In local currencies, internal sales growth was 4.8% and acquisition growth was 4.0% (see Exhibit A for details of sales growth).
Net income attributable to Henry Schein, Inc. for the third quarter of 2017 was $138.0 million, or $0.87 per diluted share. Compared with the GAAP results for the third quarter of 2016, this represents growth of 3.2% and 6.1%, respectively. Compared with the non-GAAP results for the third quarter of 2016, this represents growth of 0.2% and 3.6%, respectively. Note that third quarter 2016 non-GAAP results exclude restructuring costs of $5.4 million pretax or $0.02per diluted share (see Exhibit B for reconciliation of GAAP net income and EPS to non-GAAP net income and EPS).
“Solid overall sales results for the quarter reflect continued success with our comprehensive offering of products and value-added services that drive internal growth, complemented by strategic acquisitions,” said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein. “Third quarter sales growth was negatively impacted by approximately 30 basis points due to the recent hurricanes in the U.S. as well as a difficult comparable in dental equipment sales as we reported double-digit sales growth in the third quarter of 2016 associated with a successful sales promotion.”
Henry Schein is adjusting its 2017 full year EPS guidance range to reflect growth of approximately 12% on a GAAP basis, versus the comparable 2016 results. This reflects growth of 8% to 9% on a non-GAAP basis, which excludes litigation settlement expenses and a fourth quarter loss associated with Henry Schein’s divestiture of its equity ownership in E4D Technologies, versus the comparable 2016 results. The Company also is introducing 2018 EPS guidance that reflects growth of 11% to 14% compared with the midpoint of the Company’s 2017 GAAP guidance range and 7% to 10% compared with the midpoint of the Company’s 2017 non-GAAP guidance range.
“During 2018 and beyond, we expect to continue to make progress with our focus on increasing sales of higher-margin products, as well as improving operating efficiencies to achieve long-term EPS growth,” Mr. Bergman added.
Dental sales of $1.5 billion increased 11.1%, consisting of 9.1% growth in local currencies and a 2.0% increase related to foreign currency exchange. In local currencies, internal sales growth was 1.6% and acquisition growth was 7.5%. The 1.6% internal growth in local currencies included 0.8% growth in North America and 3.2% growth internationally.
“In North America, dental consumable merchandise internal sales growth in local currencies was 1.3%, which was negatively impacted by approximately 140 basis points due to recent hurricanes and the loss of a previously disclosed large DSO contract. We continue to expect stable market growth for dental consumable merchandise,” commented Mr. Bergman. “North America dental equipment internal sales growth in local currencies declined by 0.7%, which was negatively impacted by approximately 170 basis points due to recent hurricanes and the loss of the previously disclosed DSO contract, and reflects a difficult prior-year comparison, when we achieved 13.3% growth. We are fully committed to offering a broad set of solutions to advance digital dentistry, and are pleased with the initial reception from customers in North America following the addition of the full line of Dentsply Sirona dental equipment.”
Henry Schein now has access to a comprehensive offering of digital prosthetic equipment solutions and therefore, recently divested its equity investment in E4D Technologies. This is consistent with the Company’s strategy to offer a comprehensive selection of dental equipment solutions to customers through an open-architecture market approach. The Company also now has broad access to digital prosthetic materials and as a result, recently divested its ownership position in a company that produces materials used for manufacturing lab restorations and distributes dental products in China. Henry Schein believes it continues to be well-positioned in the global dental lab market, providing solutions for digital restorations that are outsourced to lab facilities. In addition to Dentsply Sirona, Henry Schein will continue to represent the complete lines from other key suppliers, including 3M, 3Shape, A-dec, Danaher, Ivoclar, Midmark, Planmeca, and many others.
Mr. Bergman continued, “In local currencies, international dental consumable merchandise internal sales growth was 3.4% and international dental equipment internal sales growth was 2.6%.”
Animal Health sales of $882.6 million increased 11.7%, consisting of 9.9% growth in local currencies and a 1.8% increase related to foreign currency exchange. In local currencies, internal sales growth was 8.0% and acquisition growth was 1.9%. The 8.0% internal growth in local currencies included 9.0% growth in North America, which was negatively impacted by approximately 50 basis points due to recent hurricanes, and 6.9% growth internationally.
“Global Animal Health internal sales growth in local currencies reflects strong execution across our global business,” commented Mr. Bergman. “We believe these gains are due to the breadth of our value-added solutions offering, including an enhanced product portfolio featuring software, diagnostic equipment, and surgical instruments.”
Medical sales of $690.8 million increased 8.0%, consisting of 7.9% growth in local currencies, and a 0.1% increase related to foreign currency exchange. In local currencies, internal sales growth was 7.8%, which was negatively impacted by approximately 25 basis points due to recent hurricanes, and acquisition growth was 0.1%.
“The large group practice segment of the market contributed to solid sales growth in our Medical group during the quarter. This success reflects our commitment to solutions that help customers provide quality care and increase value in the delivery of health care services,” remarked Mr. Bergman.
Technology and Value-Added Services sales of $109.0 million increased 4.1%, including 3.7% growth in local currencies and a 0.4% increase related to foreign currency exchange. In local currencies, internal sales growth was 3.0% and acquisition growth was 0.7%.
“In North America, Technology and Value-Added Services internal sales growth of 2.0% in local currencies was impacted by lower dental software sales and financial services revenue, which is primarily related to lower dental equipment sales versus the prior year third quarter,” said Mr. Bergman. “In international markets, we delivered solid internal sales growth in local currencies of 8.7%, highlighted by strong veterinary software revenue.”
Stock Repurchase Plan
The Company announced that during the third quarter it spent approximately $125.0 million to repurchase approximately 1.4 million shares of its common stock. The impact of the repurchase of shares on third quarter 2017 diluted EPS was immaterial. At the close of the third quarter, Henry Schein had approximately $425.0 millionauthorized for future repurchases of its common stock.
Year-to-Date Results
Net sales for the first nine months of 2017 were $9.1 billion, an increase of 8.2% compared with the first nine months of 2016. This consisted of 8.4% growth in local currencies and a decline of 0.2% related to foreign currency exchange. In local currencies, internal sales growth was 5.0% and acquisition growth was 3.4% (see Exhibit A for details of sales growth).
Net income attributable to Henry Schein, Inc. for the first nine months of 2017 was $414.8 million, or $2.61 per diluted share on a GAAP basis, an increase of 12.9% and 17.0%, respectively, compared with the first nine months of 2016. Excluding the second quarter 2017 litigation settlement expense of $5.3 million pretax or $0.02 per diluted share, non-GAAP net income attributable to Henry Schein, Inc. for the first nine months of 2017 was $418.0 million or $2.63 per diluted share, an increase of 7.2% and 11.0%, respectively, compared with non-GAAP results for the first nine months of 2016, which excluded restructuring costs (see Exhibit B for reconciliation of GAAP net income and EPS to non-GAAP net income and EPS).
2017 EPS Guidance
Henry Schein today adjusted its 2017 full year diluted EPS guidance range and now expects the following:
- 2017 GAAP diluted EPS attributable to Henry Schein, Inc., which includes litigation settlement expenses, is expected to be $3.46 to $3.48. This guidance reflects growth of approximately 12% compared with 2016 GAAP diluted EPS of $3.10. The prior 2017 GAAP diluted EPS guidance range was $3.57 to $3.63.
- 2017 non-GAAP diluted EPS, which excludes litigation settlement expenses and a fourth quarter loss associated with Henry Schein’s divestiture of its equity ownership in E4D Technologies, is expected to be $3.59 to $3.61. This guidance reflects growth of 8% to 9% compared with 2016 non-GAAP diluted EPS of $3.31, which excluded restructuring charges of $0.21 per diluted share. The prior 2017 non-GAAP diluted EPS guidance range was $3.59 to $3.65.
- The Company notes that fiscal year 2017 includes one less week than fiscal year 2016.
- Guidance for 2017 GAAP and non-GAAP diluted EPS is for current continuing operations as well as completed or previously announced acquisitions, and does not include the impact of potential future acquisitions, if any. Guidance also assumes foreign exchange rates that are generally consistent with current levels.
2018 EPS Guidance
Henry Schein today introduced 2018 financial guidance, as follows:
- 2018 diluted EPS attributable to Henry Schein, Inc. is expected to be $3.85 to $3.96. This guidance reflects growth of 11% to 14% compared with the midpoint of the Company’s 2017 GAAP guidance range and growth of 7% to 10% compared with the midpoint of the Company’s 2017 non-GAAP guidance range.
- Guidance for 2018 diluted EPS attributable to Henry Schein, Inc. is for current continuing operations as well as completed or previously announced acquisitions, and does not include the impact of potential future acquisitions, if any. Guidance also assumes foreign exchange rates that are generally consistent with current levels.
Third Quarter 2017 Conference Call Webcast
The Company will hold a conference call to discuss third quarter 2017 financial results today, beginning at 10:00 a.m. Eastern time. Individual investors are invited to listen to the conference call through Henry Schein’s website at www.henryschein.com. In addition, a replay will be available beginning shortly after the call has ended.
About Henry Schein, Inc.
Henry Schein, Inc. (Nasdaq: HSIC) is the world’s largest provider of health care products and services to office-based dental, animal health, and medical practitioners. The Company also serves dental laboratories, government and institutional health care clinics, and other alternate care sites. A Fortune 500® Company and a member of the S&P 500® and the Nasdaq 100® indexes, Henry Schein employs more than 22,000 Team Schein Members and serves more than 1 million customers.
The Company offers a comprehensive selection of products and services, including value-added solutions for operating efficient practices and delivering high-quality care. Henry Schein operates through a centralized and automated distribution network, with a selection of more than 120,000 branded products and Henry Schein private-brand products in stock, as well as more than 180,000 additional products available as special-order items. The Company also offers its customers exclusive, innovative technology solutions, including practice management software and e-commerce solutions, as well as a broad range of financial services.
Headquartered in Melville, N.Y., Henry Schein has operations or affiliates in 33 countries. The Company’s sales reached a record $11.6 billion in 2016, and have grown at a compound annual rate of approximately 15% since Henry Scheinbecame a public company in 1995. For more information, visit Henry Schein at www.henryschein.com, Facebook.com/HenrySchein and @HenrySchein on Twitter.
Cautionary Note Regarding Forward-Looking Statements and Use of Non-GAAP Financial Information
In accordance with the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These statements are identified by the use of such terms as “may,” “could,” “expect,” “intend,” “believe,” “plan,” “estimate,” “forecast,” “project,” “anticipate” or other comparable terms. A full discussion of our operations and financial condition, including factors that may affect our business and future prospects, is contained in documents we have filed with the United States Securities and Exchange Commission, or SEC, and will be contained in all subsequent periodic filings we make with the SEC. These documents identify in detail important risk factors that could cause our actual performance to differ materially from current expectations.
Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: effects of a highly competitive and consolidating market; our dependence on third parties for the manufacture and supply of our products; our dependence upon sales personnel, customers, suppliers and manufacturers; our dependence on our senior management; fluctuations in quarterly earnings; risks from expansion of customer purchasing power and multi-tiered costing structures; increases in shipping costs for our products or other service issues with our third-party shippers; general global macro-economic conditions; risks associated with currency fluctuations; risks associated with political and economic uncertainty; disruptions in financial markets; volatility of the market price of our common stock; changes in the health care industry; implementation of health care laws; failure to comply with regulatory requirements and data privacy laws; risks associated with our global operations; transitional challenges associated with acquisitions and joint ventures, including the failure to achieve anticipated synergies; financial risks associated with acquisitions and joint ventures; litigation risks; the dependence on our continued product development, technical support and successful marketing in the technology segment; increased competition by third party online commerce sites; risks from disruption to our information systems; cyberattacks or other privacy or data security breaches; certain provisions in our governing documents that may discourage third-party acquisitions of us; and changes in tax legislation. The order in which these factors appear should not be construed to indicate their relative importance or priority.
We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict. Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forward-looking statements.
Included within the press release are non-GAAP financial measures that supplement the Company’s Consolidated Statements of Income prepared under generally accepted accounting principles (GAAP). These non-GAAP financial measures adjust the Company’s actual results prepared under GAAP to exclude certain items. In the schedules attached to this press release, the non-GAAP measures have been reconciled to and should be considered together with the Consolidated Statements of Income. Management believes that non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance and allow for greater transparency with respect to key metrics used by management in operating our business. These non-GAAP financial measures are presented solely for informational and comparative purposes and should not be regarded as a replacement for corresponding, similarly captioned, GAAP measures.
(TABLES TO FOLLOW)
| HENRY SCHEIN, INC. | |||||||||||||||
| CONSOLIDATED STATEMENTS OF INCOME | |||||||||||||||
| (in thousands, except per share data) | |||||||||||||||
| (unaudited) | |||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||
| September 30, | September 24, | September 30, | September 24, | ||||||||||||
| 2017 | 2016 | 2017 | 2016 | ||||||||||||
| Net sales | $ | 3,161,083 | $ | 2,865,148 | $ | 9,143,489 | $ | 8,450,734 | |||||||
| Cost of sales | 2,325,029 | 2,077,473 | 6,645,342 | 6,083,748 | |||||||||||
| Gross profit | 836,054 | 787,675 | 2,498,147 | 2,366,986 | |||||||||||
| Operating expenses: | |||||||||||||||
| Selling, general and administrative | 622,506 | 581,584 | 1,879,969 | 1,779,583 | |||||||||||
| Restructuring costs | - | 5,370 | - | 29,811 | |||||||||||
| Operating income | 213,548 | 200,721 | 618,178 | 557,592 | |||||||||||
| Other income (expense): | |||||||||||||||
| Interest income | 4,793 | 3,141 | 13,204 | 10,045 | |||||||||||
| Interest expense | (13,428) | (7,488) | (37,056) | (21,982) | |||||||||||
| Other, net | (194) | (199) | 489 | 3,206 | |||||||||||
| Income before taxes and equity in earnings | |||||||||||||||
| of affiliates | 204,719 | 196,175 | 594,815 | 548,861 | |||||||||||
| Income taxes | (59,340) | (56,601) | (156,276) | (159,099) | |||||||||||
| Equity in earnings of affiliates | 5,569 | 5,717 | 12,244 | 13,160 | |||||||||||
| Net income | 150,948 | 145,291 | 450,783 | 402,922 | |||||||||||
| Less: Net income attributable to noncontrolling interests | (12,917) | (11,578) | (35,949) | (35,360) | |||||||||||
| Net income attributable to Henry Schein, Inc. | $ | 138,031 | $ | 133,713 | $ | 414,834 | $ | 367,562 | |||||||
| Earnings per share attributable to Henry Schein, Inc.: | |||||||||||||||
| Basic | $ | 0.88 | $ | 0.83 | $ | 2.64 | $ | 2.26 | |||||||
| Diluted | $ | 0.87 | $ | 0.82 | $ | 2.61 | $ | 2.23 | |||||||
| Weighted-average common shares outstanding: | |||||||||||||||
| Basic | 156,914 | 161,791 | 157,386 | 162,600 | |||||||||||
| Diluted | 158,271 | 163,710 | 158,866 | 164,635 | |||||||||||
| Note: Certain prior quarter amounts have been reclassified to conform to the current period presentation. | |||||||||||||||
| HENRY SCHEIN, INC. | |||||||||
| CONSOLIDATED BALANCE SHEETS | |||||||||
| (in thousands, except share and per share data) | |||||||||
| September 30, | December 31, | ||||||||
| 2017 | 2016 | ||||||||
| (unaudited) | |||||||||
| ASSETS | |||||||||
| Current assets: | |||||||||
| Cash and cash equivalents | $ | 79,879 | $ | 62,381 | |||||
| Accounts receivable, net of reserves of $96,953 and $90,329 | 1,544,582 | 1,254,139 | |||||||
| Inventories, net | 1,692,256 | 1,635,750 | |||||||
| Prepaid expenses and other | 465,812 | 360,510 | |||||||
| Total current assets | 3,782,529 | 3,312,780 | |||||||
| Property and equipment, net | 361,708 | 333,906 | |||||||
| Goodwill | 2,224,657 | 2,019,740 | |||||||
| Other intangibles, net | 666,997 | 621,180 | |||||||
| Investments and other | 450,770 | 442,790 | |||||||
| Total assets | $ | 7,486,661 | $ | 6,730,396 | |||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||
| Current liabilities: | |||||||||
| Accounts payable | $ | 1,029,138 | $ | 977,249 | |||||
| Bank credit lines | 631,865 | 437,476 | |||||||
| Current maturities of long-term debt | 17,247 | 65,923 | |||||||
| Accrued expenses: | |||||||||
| Payroll and related | 251,849 | 266,463 | |||||||
| Taxes | 148,627 | 151,750 | |||||||
| Other | 358,421 | 391,785 | |||||||
| Total current liabilities | 2,437,147 | 2,290,646 | |||||||
| Long-term debt | 907,592 | 715,457 | |||||||
| Deferred income taxes | 91,786 | 51,589 | |||||||
| Other liabilities | 292,179 | 264,264 | |||||||
| Total liabilities | 3,728,704 | 3,321,956 | |||||||
| Redeemable noncontrolling interests | 737,747 | 607,636 | |||||||
| Commitments and contingencies | |||||||||
| Stockholders’ equity: | |||||||||
| Preferred stock, $.01 par value, 1,000,000 shares authorized, | |||||||||
| none outstanding | - | - | |||||||
| Common stock, $.01 par value, 240,000,000 shares authorized, | |||||||||
| 156,952,738 outstanding on September 30, 2017 and | |||||||||
| 158,805,010 outstanding on December 31, 2016 | 1,570 | 1,588 | |||||||
| Additional paid-in capital | - | 126,742 | |||||||
| Retained earnings | 3,164,541 | 2,981,777 | |||||||
| Accumulated other comprehensive loss | (154,472) | (317,041) | |||||||
| Total Henry Schein, Inc. stockholders’ equity | 3,011,639 | 2,793,066 | |||||||
| Noncontrolling interests | 8,571 | 7,738 | |||||||
| Total stockholders’ equity | 3,020,210 | 2,800,804 | |||||||
| Total liabilities, redeemable noncontrolling interests and stockholders’ equity | $ | 7,486,661 | $ | 6,730,396 | |||||
| Note: Certain prior period amounts have been reclassified to conform to the current period presentation. | |||||||||
| HENRY SCHEIN, INC. | ||||||||||||||||
| CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||||||||||
| (in thousands) | ||||||||||||||||
| (unaudited) | ||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 24, | September 30, | September 24, | |||||||||||||
| 2017 | 2016 | 2017 | 2016 | |||||||||||||
| Cash flows from operating activities: | ||||||||||||||||
| Net income | $ | 150,948 | $ | 145,291 | $ | 450,783 | $ | 402,922 | ||||||||
| Adjustments to reconcile net income to net cash | ||||||||||||||||
| provided by operating activities: | ||||||||||||||||
| Depreciation and amortization | 48,740 | 42,431 | 141,278 | 125,829 | ||||||||||||
| Stock-based compensation expense | 12,632 | 16,171 | 31,987 | 43,627 | ||||||||||||
| Provision for losses on trade and other | ||||||||||||||||
| accounts receivable | 2,932 | 946 | 6,981 | 1,736 | ||||||||||||
| Provision for (benefit from) deferred income taxes | 4,185 | (8,767) | 8,600 | (13,425) | ||||||||||||
| Equity in earnings of affiliates | (5,569) | (5,717) | (12,244) | (13,160) | ||||||||||||
| Distributions from equity affiliates | 7,148 | 5,767 | 16,826 | 12,104 | ||||||||||||
| Changes in unrecognized tax benefits | 974 | 2,348 | (6,653) | 4,799 | ||||||||||||
| Other | 1,016 | 5,484 | 6,031 | 7,845 | ||||||||||||
| Changes in operating assets and liabilities, | ||||||||||||||||
| net of acquisitions: | ||||||||||||||||
| Accounts receivable | (106,301) | (74,884) | (229,239) | (131,586) | ||||||||||||
| Inventories | (88,464) | 14,118 | 27,336 | 48,513 | ||||||||||||
| Other current assets | (13,134) | 3,095 | (70,833) | (35,781) | ||||||||||||
| Accounts payable and accrued expenses | 116,255 | 32,346 | (63,352) | (75,355) | ||||||||||||
| Net cash provided by operating activities | 131,362 | 178,629 | 307,501 | 378,068 | ||||||||||||
| Cash flows from investing activities: | ||||||||||||||||
| Purchases of fixed assets | (18,350) | (18,345) | (55,315) | (44,525) | ||||||||||||
| Payments for equity investments and business | ||||||||||||||||
| acquisitions, net of cash acquired | (109,200) | (34,102) | (258,786) | (126,543) | ||||||||||||
| Other | (1,822) | (7,001) | (6,694) | (8,766) | ||||||||||||
| Net cash used in investing activities | (129,372) | (59,448) | (320,795) | (179,834) | ||||||||||||
| Cash flows from financing activities: | ||||||||||||||||
| Proceeds from (repayments of) bank borrowings | 54,288 | 94,205 | 193,550 | (3,274) | ||||||||||||
| Proceeds from issuance of long-term debt | 100,440 | 16,000 | 200,440 | 260,000 | ||||||||||||
| Principal payments for long-term debt | (347) | (1,372) | (59,531) | (9,293) | ||||||||||||
| Debt issuance costs | (638) | - | (1,771) | (233) | ||||||||||||
| Proceeds from issuance of stock upon exercise | ||||||||||||||||
| of stock options | 240 | 695 | 4,941 | 9,754 | ||||||||||||
| Payments for repurchases of common stock | (124,999) | (192,992) | (225,005) | (350,001) | ||||||||||||
| Payments for taxes related to shares withheld for employee taxes | (307) | (548) | (44,721) | (27,115) | ||||||||||||
| Excess tax benefits related to stock-based | ||||||||||||||||
| compensation | - | (463) | - | (463) | ||||||||||||
| Distributions to noncontrolling shareholders | (4,320) | (6,206) | (23,921) | (26,366) | ||||||||||||
| Acquisitions of noncontrolling interests in subsidiaries | (23,763) | (15,633) | (27,914) | (51,265) | ||||||||||||
| Net cash provided by (used in) financing activities | 594 | (106,314) | 16,068 | (198,256) | ||||||||||||
| Effect of exchange rate changes on cash and | ||||||||||||||||
| cash equivalents | 2,641 | (235) | 14,724 | 4,128 | ||||||||||||
| Net change in cash and cash equivalents | 5,225 | 12,632 | 17,498 | 4,106 | ||||||||||||
| Cash and cash equivalents, beginning of period | 74,654 | 63,560 | 62,381 | 72,086 | ||||||||||||
| Cash and cash equivalents, end of period | $ | 79,879 | $ | 76,192 | $ | 79,879 | $ | 76,192 | ||||||||
| Note: Certain prior period amounts have been reclassified to conform to the current period presentation. | ||||||||||||||||
| Exhibit A - QTD Sales | |||||||||||||||
| Henry Schein, Inc. | |||||||||||||||
| 2017 Third Quarter | |||||||||||||||
| Sales Summary | |||||||||||||||
| (in thousands) | |||||||||||||||
| (unaudited) | |||||||||||||||
| Q3 2017 over Q3 2016 | |||||||||||||||
| Global | Q3 2017 | Q3 2016 | Total Sales Growth | Foreign Exchange Growth | Local Currency Growth | Acquisition Growth | Local Internal Growth | ||||||||
| Dental | $ | 1,478,730 | $ | 1,330,525 | 11.1% | 2.0% | 9.1% | 7.5% | 1.6% | ||||||
| Animal Health | 882,580 | 790,279 | 11.7% | 1.8% | 9.9% | 1.9% | 8.0% | ||||||||
| Medical | 690,761 | 639,648 | 8.0% | 0.1% | 7.9% | 0.1% | 7.8% | ||||||||
| Total Health Care Distribution | 3,052,071 | 2,760,452 | 10.6% | 1.6% | 9.0% | 4.1% | 4.9% | ||||||||
| Technology and value-added services | 109,012 | 104,696 | 4.1% | 0.4% | 3.7% | 0.7% | 3.0% | ||||||||
| Total Global | $ | 3,161,083 | $ | 2,865,148 | 10.3% | 1.5% | 8.8% | 4.0% | 4.8% | ||||||
| North America | Q3 2017 | Q3 2016 | Total Sales Growth | Foreign Exchange Growth | Local Currency Growth | Acquisition Growth | Local Internal Growth | ||||||||
| Dental | $ | 906,878 | $ | 879,612 | 3.1% | 0.4% | 2.7% | 1.9% | 0.8% | ||||||
| Animal Health | 448,376 | 403,901 | 11.0% | 0.0% | 11.0% | 2.0% | 9.0% | ||||||||
| Medical | 672,425 | 622,903 | 8.0% | 0.0% | 8.0% | 0.1% | 7.9% | ||||||||
| Total Health Care Distribution | 2,027,679 | 1,906,416 | 6.4% | 0.2% | 6.2% | 1.3% | 4.9% | ||||||||
| Technology and value-added services | 89,881 | 88,066 | 2.1% | 0.1% | 2.0% | 0.0% | 2.0% | ||||||||
| Total North America | $ | 2,117,560 | $ | 1,994,482 | 6.2% | 0.2% | 6.0% | 1.3% | 4.7% | ||||||
| International | Q3 2017 | Q3 2016 | Total Sales Growth | Foreign Exchange Growth | Local Currency Growth | Acquisition Growth | Local Internal Growth | ||||||||
| Dental | $ | 571,852 | $ | 450,913 | 26.8% | 5.3% | 21.5% | 18.3% | 3.2% | ||||||
| Animal Health | 434,204 | 386,378 | 12.4% | 3.6% | 8.8% | 1.9% | 6.9% | ||||||||
| Medical | 18,336 | 16,745 | 9.5% | 5.0% | 4.5% | 0.0% | 4.5% | ||||||||
| Total Health Care Distribution | 1,024,392 | 854,036 | 19.9% | 4.5% | 15.4% | 10.5% | 4.9% | ||||||||
| Technology and value-added services | 19,131 | 16,630 | 15.0% | 1.8% | 13.2% | 4.5% | 8.7% | ||||||||
| Total International | $ | 1,043,523 | $ | 870,666 | 19.9% | 4.5% | 15.4% | 10.4% | 5.0% | ||||||
| Exhibit A - YTD Sales | |||||||||||||||
| Henry Schein, Inc. | |||||||||||||||
| 2017 Third Quarter Year to Date | |||||||||||||||
| Sales Summary | |||||||||||||||
| (in thousands) | |||||||||||||||
| (unaudited) | |||||||||||||||
| Q3 2017 YTD over Q3 2016 YTD | |||||||||||||||
| Global | Q3 2017 YTD | Q3 2016 YTD | Total Sales Growth | Foreign Exchange Growth | Local Currency Growth | Acquisition Growth | Local Internal Growth | ||||||||
| Dental | $ | 4,372,055 | $ | 4,005,468 | 9.2% | 0.3% | 8.9% | 6.3% | 2.6% | ||||||
| Animal Health | 2,586,850 | 2,415,290 | 7.1% | -1.1% | 8.2% | 1.3% | 6.9% | ||||||||
| Medical | 1,861,074 | 1,716,590 | 8.4% | -0.1% | 8.5% | 0.1% | 8.4% | ||||||||
| Total Health Care Distribution | 8,819,979 | 8,137,348 | 8.4% | -0.2% | 8.6% | 3.5% | 5.1% | ||||||||
| Technology and value-added services | 323,510 | 313,386 | 3.2% | -0.8% | 4.0% | 0.4% | 3.6% | ||||||||
| Total Global | $ | 9,143,489 | $ | 8,450,734 | 8.2% | -0.2% | 8.4% | 3.4% | 5.0% | ||||||
| North America | Q3 2017 YTD | Q3 2016 YTD | Total Sales Growth | Foreign Exchange Growth | Local Currency Growth | Acquisition Growth | Local Internal Growth | ||||||||
| Dental | $ | 2,669,805 | $ | 2,580,034 | 3.5% | 0.1% | 3.4% | 1.6% | 1.8% | ||||||
| Animal Health | 1,344,221 | 1,249,146 | 7.6% | 0.0% | 7.6% | 0.8% | 6.8% | ||||||||
| Medical | 1,806,196 | 1,662,676 | 8.6% | 0.0% | 8.6% | 0.0% | 8.6% | ||||||||
| Total Health Care Distribution | 5,820,222 | 5,491,856 | 6.0% | 0.1% | 5.9% | 0.9% | 5.0% | ||||||||
| Technology and value-added services | 269,226 | 264,191 | 1.9% | 0.0% | 1.9% | 0.0% | 1.9% | ||||||||
| Total North America | $ | 6,089,448 | $ | 5,756,047 | 5.8% | 0.1% | 5.7% | 0.9% | 4.8% | ||||||
| International | Q3 2017 YTD | Q3 2016 YTD | Total Sales Growth | Foreign Exchange Growth | Local Currency Growth | Acquisition Growth | Local Internal Growth | ||||||||
| Dental | $ | 1,702,250 | $ | 1,425,434 | 19.4% | 0.5% | 18.9% | 15.0% | 3.9% | ||||||
| Animal Health | 1,242,629 | 1,166,144 | 6.6% | -2.2% | 8.8% | 1.7% | 7.1% | ||||||||
| Medical | 54,878 | 53,914 | 1.8% | -1.3% | 3.1% | 0.0% | 3.1% | ||||||||
| Total Health Care Distribution | 2,999,757 | 2,645,492 | 13.4% | -0.7% | 14.1% | 8.8% | 5.3% | ||||||||
| Technology and value-added services | 54,284 | 49,195 | 10.3% | -5.0% | 15.3% | 2.6% | 12.7% | ||||||||
| Total International | $ | 3,054,041 | $ | 2,694,687 | 13.3% | -0.8% | 14.1% | 8.7% | 5.4% | ||||||
| Exhibit B | |||||||||||||||||
| Henry Schein, Inc. | |||||||||||||||||
| 2017 Third Quarter and YTD | |||||||||||||||||
| Reconciliation of GAAP results of net income attributable to Henry Schein, Inc. to | |||||||||||||||||
| non-GAAP results of net income attributable to Henry Schein, Inc. | |||||||||||||||||
| (in thousands, except per share data) | |||||||||||||||||
| (unaudited) | |||||||||||||||||
| Third Quarter | Year-to-Date | ||||||||||||||||
| % | % | ||||||||||||||||
| 2017 | 2016 | Growth | 2017 | 2016 | Growth | ||||||||||||
| Net Income attributable to Henry Schein, Inc. | $ | 138,031 | $ | 133,713 | 3.2 | % | $ | 414,834 | $ | 367,562 | 12.9 | % | |||||
| Diluted EPS attributable to Henry Schein, Inc. | $ | 0.87 | $ | 0.82 | 6.1 | % | $ | 2.61 | $ | 2.23 | 17.0 | % | |||||
| Non-GAAP Adjustments | |||||||||||||||||
| Restructuring costs - Pre-tax | $ | - | $ | 5,370 | $ | - | $ | 29,811 | |||||||||
| Income tax benefit for restructuring costs | - | (1,343) | - | (7,453) | |||||||||||||
| Litigation settlement - Pre-Tax | - | - | 5,325 | - | |||||||||||||
| Income tax benefit for litigation settlement | - | - | (2,130) | - | |||||||||||||
| Total non-GAAP adjustments to Net Income | $ | - | $ | 4,027 | $ | 3,195 | $ | 22,358 | |||||||||
| Non-GAAP Adjustments to diluted EPS | $ | - | $ | 0.02 | $ | 0.02 | $ | 0.14 | |||||||||
| Non-GAAP Net Income attributable to Henry Schein, Inc. | $ | 138,031 | $ | 137,740 | 0.2 | % | $ | 418,029 | $ | 389,920 | 7.2 | % | |||||
| Non-GAAP diluted EPS attributable to Henry Schein, Inc. | $ | 0.87 | $ | 0.84 | 3.6 | % | $ | 2.63 | $ | 2.37 | 11.0 | % | |||||
Management believes that non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance and allow for greater transparency with respect to key metrics used by management in operating our business. These non-GAAP financial measures are presented solely for informational and comparative purposes and should not be regarded as a replacement for corresponding, similarly captioned, GAAP measures.
SOURCE Henry Schein, Inc.
